A business in context
TVTX research notebook
Read the disclosures. Follow the relationships. Keep the dates in view.
Filing timeline
Download filings CSVReported insider transactions
Download transactions CSVP · PurchaseS · SaleA · Grant / awardM · Exercise / conversionF · Tax / exercise paymentG · Gift
| Transaction / filed | Reporting owner | Type | Security | Shares | Reported price |
|---|---|---|---|---|---|
| 2026-05-04 | Dube Eric M | M · Exercise / conversion | Common Stock | 22500.0 | 0.0 |
| 2026-05-04 | Dube Eric M | M · Exercise / conversion | Performance-based restricted stock units | 22500.0 | 0.0 |
| 2026-05-04 | Dube Eric M | A · Grant / award | Performance-based restricted stock units | 45000.0 | 0.0 |
| 2026-05-04 | ROTE WILLIAM E. | M · Exercise / conversion | Common Stock | 4250.0 | 0.0 |
| 2026-05-04 | ROTE WILLIAM E. | A · Grant / award | Performance-based restricted stock units | 8500.0 | 0.0 |
| 2026-05-04 | ROTE WILLIAM E. | M · Exercise / conversion | Performance-based restricted stock units | 4250.0 | 0.0 |
| 2026-05-04 | Meckler Jeffrey A | M · Exercise / conversion | Common Stock | 8000.0 | 16.33 |
| 2026-05-04 | Meckler Jeffrey A | S · Sale | Common Stock | 8000.0 | 45.0 |
| 2026-05-04 | Meckler Jeffrey A | M · Exercise / conversion | Stock option (right to buy) | 8000.0 | 0.0 |
| 2026-05-04 | REED ELIZABETH E | M · Exercise / conversion | Common Stock | 4250.0 | 0.0 |
| 2026-05-04 | REED ELIZABETH E | S · Sale | Common Stock | 20000.0 | 45.0 |
| 2026-05-04 | REED ELIZABETH E | M · Exercise / conversion | Common Stock | 20000.0 | 17.96 |
| 2026-05-04 | REED ELIZABETH E | M · Exercise / conversion | Employee stock option (right to buy) | 20000.0 | 0.0 |
| 2026-05-04 | REED ELIZABETH E | M · Exercise / conversion | Performance-based restricted stock units | 4250.0 | 0.0 |
| 2026-05-04 | REED ELIZABETH E | A · Grant / award | Performance-based restricted stock units | 8500.0 | 0.0 |
| 2026-05-01 | Baynes Roy D. | S · Sale | Common Stock | 9750.0 | 44.22 |
| 2026-05-01 | Baynes Roy D. | M · Exercise / conversion | Common Stock | 9750.0 | 6.82 |
| 2026-05-01 | Baynes Roy D. | M · Exercise / conversion | Stock option (right to buy) | 9750.0 | 0.0 |
| 2026-04-22 | ROTE WILLIAM E. | S · Sale | Common Stock | 9100.0 | 39.09 |
| 2026-04-15 | Cline Christopher R. | S · Sale | Common Stock | 1014.0 | 42.61 |
| 2026-04-15 | Inrig Jula | S · Sale | Common Stock | 1018.0 | 42.61 |
| 2026-04-15 | Dube Eric M | S · Sale | Common Stock | 56815.0 | 41.01 |
| 2026-04-15 | Dube Eric M | S · Sale | Common Stock | 20.0 | 42.66 |
| 2026-04-15 | Dube Eric M | S · Sale | Common Stock | 7165.0 | 41.75 |
| 2026-04-15 | REED ELIZABETH E | S · Sale | Common Stock | 1559.0 | 42.53 |
| 2026-04-15 | REED ELIZABETH E | S · Sale | Common Stock | 5226.0 | 41.62 |
| 2026-04-14 | Cline Christopher R. | S · Sale | Common Stock | 7239.0 | 41.93 |
| 2026-04-14 | Cline Christopher R. | S · Sale | Common Stock | 9.0 | 41.07 |
| 2026-04-14 | Inrig Jula | S · Sale | Common Stock | 7215.0 | 41.93 |
| 2026-04-14 | Calvin Sandra | M · Exercise / conversion | Common Stock | 6250.0 | 8.93 |
| 2026-04-14 | Calvin Sandra | M · Exercise / conversion | Common Stock | 2500.0 | 22.4 |
| 2026-04-14 | Calvin Sandra | M · Exercise / conversion | Common Stock | 6500.0 | 20.46 |
| 2026-04-14 | Calvin Sandra | S · Sale | Common Stock | 21977.0 | 41.07 |
| 2026-04-14 | Calvin Sandra | M · Exercise / conversion | Employee stock option (right to buy) | 2500.0 | 0.0 |
| 2026-04-14 | Calvin Sandra | M · Exercise / conversion | Employee stock option (right to buy) | 6250.0 | 0.0 |
| 2026-04-14 | Calvin Sandra | M · Exercise / conversion | Employee stock option (right to buy) | 6500.0 | 0.0 |
| 2026-04-14 | Heerma Peter | S · Sale | Common Stock | 7215.0 | 41.93 |
| 2026-04-14 | Baynes Roy D. | S · Sale | Common Stock | 26000.0 | 41.07 |
| 2026-04-14 | Baynes Roy D. | S · Sale | Common Stock | 6750.0 | 42.12 |
| 2026-04-14 | Baynes Roy D. | M · Exercise / conversion | Common Stock | 6750.0 | 17.11 |
| 2026-04-14 | Baynes Roy D. | M · Exercise / conversion | Common Stock | 4500.0 | 21.38 |
| 2026-04-14 | Baynes Roy D. | M · Exercise / conversion | Common Stock | 4500.0 | 18.27 |
| 2026-04-14 | Baynes Roy D. | M · Exercise / conversion | Common Stock | 9000.0 | 15.43 |
| 2026-04-14 | Baynes Roy D. | M · Exercise / conversion | Common Stock | 8000.0 | 17.94 |
| 2026-04-14 | Baynes Roy D. | M · Exercise / conversion | Stock option (right to buy) | 6750.0 | 0.0 |
| 2026-04-14 | Baynes Roy D. | M · Exercise / conversion | Stock option (right to buy) | 4500.0 | 0.0 |
| 2026-04-14 | Baynes Roy D. | M · Exercise / conversion | Stock option (right to buy) | 4500.0 | 0.0 |
| 2026-04-14 | Baynes Roy D. | M · Exercise / conversion | Stock option (right to buy) | 9000.0 | 0.0 |
| 2026-04-14 | Baynes Roy D. | M · Exercise / conversion | Stock option (right to buy) | 8000.0 | 0.0 |
| 2026-04-14 | REED ELIZABETH E | S · Sale | Common Stock | 37500.0 | 41.07 |
Identity & relationships
SEC issuer · 0001438533Travere Therapeutics, Inc.
Search names and former names
- Retrophin, Inc. · former SEC name · 2013-02-21 to 2020-11-13
- Desert Gateway, Inc. · former SEC name · 2008-06-27 to 2013-02-19
Revenue in constant purchasing power
| Year ended | Reported USD revenue | CPI-adjusted USD revenue |
|---|---|---|
| 2024-12-31 | $233.18M | $248.21M |
| 2023-12-31 | $145.24M | $159.15M |
| 2022-12-31 | $109.46M | $124.87M |
| 2021-12-31 | $131.84M | $162.43M |
| 2020-12-31 | $198.32M | $255.87M |
| 2019-12-31 | $175.34M | $229.00M |
| 2018-12-31 | $164.25M | $218.40M |
| 2017-12-31 | $154.94M | $211.06M |